|
ホンダ ゴロウ
HONDA Gorou
本田 五郎 所属 医学部 医学科（東京女子医科大学病院） 職種 教授・基幹分野長 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | Is multidisciplinary treatment effective for invasive intraductal papillary mucinous carcinoma? |
| 掲載誌名 | 正式名：Annals of gastroenterological surgery 略 称：Ann Gastroenterol Surg ISSNコード：24750328/24750328 |
| 掲載区分 | 国内 |
| 巻・号・頁 | 8(5),pp.845-859 |
| 著者・共著者 | HORONO Seiko, HIGUCHI Ryota, HONDA Goro, NARA Satoshi, ESAKI Minoru, GOTOHDA Naoto, TAKAMI Hideki, UNNO Michiaki, SUGIURA Teiichi, OHTSUKA Masayuki, SHIMIZU Yasuhiro, MATSUMOTO Ippei, KIN Toshifumi, ISAYAMA Hiroyuki, HASHIMOTO Daisuke, SEYAMA Yasuji, NAGANO Hiroaki, HAKAMADA Kenichi, HIRANO Satoshi, NAGAKAWA Yuichi, MIZUNO Shugo, TAKAHASHI Hidenori, SHIBUYA Kazuto, SASANUMA Hideki, AOKI Taku, KOHARA Yuichiro, RIKIYAMA Toshiki, NAKAMURA Masafumi, ENDO Itaru, SAKAMOTO Yoshihiro, HORIGUCHI Akihiko, HATORI Takashi, AKITA Hirofumi, UEKI Toshiharu, IDHICHI Tetsuya, HANADA Keiji, SUZUKI Shuji, OKANO Keiichi, MAEHIRA Hiromitsu, MOTOI Fuyuhiko, FUJINO Yasuhiro, TANNO Satoshi, YANAGISAWA Akio, TAKEYAMA Yoshifumi, OKAZAKI Kazuichi, SATOI Sohei, YAMAUE Hiroki |
| 発行年月 | 2024/09 |
| 概要 | BACKGROUND:Surgical resection is standard treatment for invasive intraductal papillary mucinous carcinoma (IPMC); however, impact of multidisciplinary treatment on survival including postoperative adjuvant therapy (AT), neoadjuvant therapy (NAT), and treatment for recurrent lesions is unclear. We investigated the effectiveness of multidisciplinary treatment in prolonging survival of patients with invasive IPMC.METHODS:This retrospective multi-institutional study included 1183 patients with invasive IPMC undergoing surgery at 40 academic institutions. We analyzed the effects of AT, NAT, and treatment for recurrence on survival of patients with invasive IPMC.RESULTS:Completion of the planned postoperative AT for 6 months improved the overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) of patients with stage IIB and stage III resected invasive IPMC, elevated preoperative carbohydrate antigen 19-9 level, lymphovascular invasion, perineural invasion, serosal invasion, and lymph node metastasis on un-matched and matched analyses. Of the patients with borderline resectable (BR) invasive IPMC, the OS (p = 0.001), DSS (p = 0.001), and RFS (p = 0.001) of patients undergoing NAT was longer than that of those without on the matched analysis. Of the 484 invasive IPMC patients (40.9%) who developed recurrence after surgery, the OS of 365 patients who received any treatment for recurrence was longer than that of those without treatment (40.6 vs. 22.4 months, p < 0.001).CONCLUSION:Postoperative AT might benefit selected patients with invasive IPMC, especially those at high risk of poor survival. NAT might improve the survivability of BR invasive IPMC. Any treatment for recurrence after surgery for invasive IPMC might improve survival. |
| DOI | 10.1002/ags3.12790 |
| PMID | 39229554 |